Shopping Cart
- Remove All
- Your shopping cart is currently empty
Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα, blocking IL-4Rα-mediated signaling. It is used in studies of atopic dermatitis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $247 | In Stock | |
5 mg | $619 | In Stock | |
10 mg | $993 | In Stock | |
25 mg | $1,470 | In Stock | |
50 mg | $1,980 | In Stock |
Description | Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα, blocking IL-4Rα-mediated signaling. It is used in studies of atopic dermatitis. |
In vitro | Stapokibart showed high affinity binding to IL-4Rα in human, cynomophage monkey and rat with equilibrium dissociation constant (KD) values of 0.25, 1.5 and 2.75 nM and IC50 values of 0.40 nM, respectively. In HEK293-STAT6 reporter cells, Stapokibart showed concentration-dependent inhibition of IL-4 - or IL-13-induced STAT6 activation, with IC50 values of 0.039 nM and 0.041 nM, respectively. In TF-1 cells, Stapokibart effectively inhibited IL-4 and IL-13-induced cell proliferation, with IC50 values of 1.75 nM and 0.13 nM, respectively. [1] |
In vivo | In an OVA-induced asthma model, Stapokibart showed protective effects against IL-4/IL-13 induced airway inflammation in rats. Stapokibart (25, 50, 100 mg/kg) reduces disease severity of OVA-induced rhinitis in rats. [1] |
Alias | CM310, CM 310 |
Cas No. | 2734715-10-5 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.